February 5, 2025, the FDA granted Fast Track designation to ADI-001, an investigational allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapy for the treatment of relapsed/refractory class III or class IV lupus nephritis, & nd SLE with extrarenal Dz… https://t.co/ywXUTKSoB2 https://t.co/Es0F63MBrk